Browse LRRC19

Summary
SymbolLRRC19
Nameleucine rich repeat containing 19
Aliases FLJ21302; Leucine-rich repeat-containing protein 19
Chromosomal Location9p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type I membrane protein
Domain PF13855 Leucine rich repeat
Function

-

> Gene Ontology
 
Biological Process GO:0001933 negative regulation of protein phosphorylation
GO:0006469 negative regulation of protein kinase activity
GO:0007259 JAK-STAT cascade
GO:0033673 negative regulation of kinase activity
GO:0042326 negative regulation of phosphorylation
GO:0046425 regulation of JAK-STAT cascade
GO:0046426 negative regulation of JAK-STAT cascade
GO:0051348 negative regulation of transferase activity
GO:0097696 STAT cascade
GO:1902532 negative regulation of intracellular signal transduction
GO:1904892 regulation of STAT cascade
GO:1904893 negative regulation of STAT cascade
Molecular Function GO:0004857 enzyme inhibitor activity
GO:0004860 protein kinase inhibitor activity
GO:0019207 kinase regulator activity
GO:0019210 kinase inhibitor activity
GO:0019887 protein kinase regulator activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolLRRC19
Nameleucine rich repeat containing 19
Aliases FLJ21302; Leucine-rich repeat-containing protein 19
Chromosomal Location9p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LRRC19 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolLRRC19
Nameleucine rich repeat containing 19
Aliases FLJ21302; Leucine-rich repeat-containing protein 19
Chromosomal Location9p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LRRC19 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLRRC19
Nameleucine rich repeat containing 19
Aliases FLJ21302; Leucine-rich repeat-containing protein 19
Chromosomal Location9p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LRRC19 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2450.686
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4340.727
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0060.997
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2540.778
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0910.939
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6410.0128
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolLRRC19
Nameleucine rich repeat containing 19
Aliases FLJ21302; Leucine-rich repeat-containing protein 19
Chromosomal Location9p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LRRC19. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLRRC19
Nameleucine rich repeat containing 19
Aliases FLJ21302; Leucine-rich repeat-containing protein 19
Chromosomal Location9p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LRRC19. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LRRC19.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLRRC19
Nameleucine rich repeat containing 19
Aliases FLJ21302; Leucine-rich repeat-containing protein 19
Chromosomal Location9p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LRRC19. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLRRC19
Nameleucine rich repeat containing 19
Aliases FLJ21302; Leucine-rich repeat-containing protein 19
Chromosomal Location9p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LRRC19 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLRRC19
Nameleucine rich repeat containing 19
Aliases FLJ21302; Leucine-rich repeat-containing protein 19
Chromosomal Location9p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LRRC19 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLRRC19
Nameleucine rich repeat containing 19
Aliases FLJ21302; Leucine-rich repeat-containing protein 19
Chromosomal Location9p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LRRC19 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.